Skip to main content

Market Overview

Stifel Drops Bullish Zoetis Thesis After 108% Outperformance

Stifel Drops Bullish Zoetis Thesis After 108% Outperformance

The bullish case for Zoetis Inc (NYSE: ZTS) has come to an end after the stock outperformed the S&P 500 index by 108 percent since spinning out from Pfizer Inc. (NYSE: PFE), according to Stifel.

The Analyst

Stifel's Jonathan Block downgraded Zoetis from Buy to Hold with a $95 price target. 

The Thesis

Zoetis' management team deserves credit for "near-flawless" execution over the years, but the time to buy the stock has passed, Block said in the downgrade note. (See his track record here.)

On the product side, the company's "Big 3" products — Apoquel, Cytopoint and Simparica — accounted for 50 percent of revenue growth in 2016 and 56 percent of revenue growth in 2017. The law of large numbers suggests a slowdown of growth in 2019 and 2020, and any new material product cycle in the pipeline is unlikely to be seen within the next 18 months, the analyst said. 

The cattle business, especially dairy, remains under pressure and comps will become increasingly difficult in the coming quarters, Block said. It's hard to imagine a scenario of revenue upside with the product cycle being several years old, he said. 

Zoetis shares are trading at 27 times 2019 estimated EPS and 24 times 2020 EPS estimated EPS, which implies a 57-percent premium to the S&P 500 index versus the three-year average of 37 percent, Block said. A premium valuation is warranted, but at current levels the case to justify incremental expansion is difficult to make, he said. 

Price Action

Zoetis shares were trading down 2.35 percent to $89.93 off the open Wednesday. 

Related Links:

Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target

Analyst: Zoetis Deserves To Trade At A Premium

Latest Ratings for ZTS

Feb 2021Credit SuisseMaintainsOutperform
Nov 2020Morgan StanleyMaintainsEqual-Weight
Sep 2020Atlantic EquitiesInitiates Coverage OnOverweight

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings


Related Articles (ZTS)

View Comments and Join the Discussion!

Posted-In: cattle Dairy Jonathan Block Pet CareAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at